Science Explorer Back to mapMap

Most cited papers from TetraLogic Pharmaceuticals (United States)

TetraLogic Pharmaceuticals (United States)

What are the most cited papers from TetraLogic Pharmaceuticals (United States)?

The most cited paper from TetraLogic Pharmaceuticals (United States) is "IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis" (James Edward Vince, Wendy Wei-Lynn Wong, Nufail R. Khan et al., 2007), with 1,071 citations. Next come "Reproducibility in Science" (1,070) and "RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL" (655).

Showing 50 of 60 papers. Every paper with more than 38 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis James Edward Vince, Wendy Wei-Lynn Wong, Nufail R. Khan et al. · Cell Open access Nov 2007 1,071
2 Reproducibility in Science C. Glenn Begley, John P. A. Ioannidis · Circulation Research 31 Dec 2014 1,070
3 RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL Kate E. Lawlor, Nufail R. Khan, Alison Mildenhall et al. · Nature Communications Open access 18 Feb 2015 655
4 Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis Sabrina Paganoni et al. · New England Journal of Medicine Open access 2 Sep 2020 542
5 A Novel Mutation in the Cystic Fibrosis Gene in Patients with Pulmonary Disease but Normal Sweat Chloride Concentrations William Edward Highsmith, Lauranell H. Burch, Zhaoqing Zhou et al. · New England Journal of Medicine Open access 13 Oct 1994 443
6 Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis George Trichonas, Yusuke Murakami, Aristomenis Thanos et al. · Proceedings of the National Academy of Sciences Open access 22 Nov 2010 315
7 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial Hilkka S. Soininen et al. · The Lancet Neurology Open access 30 Oct 2017 247
8 TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα James Edward Vince, Diep Chau, Bernard Andrew Callus et al. · The Journal of Cell Biology Open access 7 Jul 2008 238
9 Six red flags for suspect work C. Glenn Begley · Nature Open access 21 May 2013 233
10 Donanemab: Appropriate use recommendations G D Rabinovici, D. J. Selkoe, Suzanne Elizabeth Schindler et al. · The Journal of Prevention of Alzheimer s Disease Open access 29 Mar 2025 228
11 Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes Jong J. Kirn, Mark L. Bagarazzi, Neil N. Trivedi et al. · Nature Biotechnology Jul 1997 221
12 Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial BRIAN A. LAWLOR et al. · PLoS Medicine Open access 24 Sep 2018 207
13 Aducanumab: Appropriate Use Recommendations Update Jeffrey L. Cummings, Gil D. Rabinovici, Alireza Atri et al. · The Journal of Prevention of Alzheimer s Disease Open access 30 Mar 2022 197
14 The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia Gabriela Brumatti et al. · Science Translational Medicine Open access 18 May 2016 189
15 Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis Sabrina Paganoni et al. · Muscle & Nerve Open access 16 Oct 2020 185
16 Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models Christopher A. Benetatos et al. · Molecular Cancer Therapeutics 22 Feb 2014 180
17 Report of the task force on designing clinical trials in early (predementia) AD Paul S. S Aisen et al. · Neurology Open access 23 Dec 2010 173
18 Smac Mimetics Activate the E3 Ligase Activity of cIAP1 Protein by Promoting RING Domain Dimerization Rebecca Feltham, Bodhi Bettjeman, Rhesa Budhidarmo et al. · Journal of Biological Chemistry Open access 10 Mar 2011 169
19 ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials Jinping Wang, Veronika Logovinsky, Suzanne B. Hendrix et al. · Journal of Neurology Neurosurgery & Psychiatry Open access 23 Mar 2016 164
20 Robust research: Institutions must do their part for reproducibility C. Glenn Begley, Alastair Mitchell Buchan, Ulrich Dirnagl · Nature Open access Sep 2015 164
21 A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study Merçé Boada, Oscar L. López, Javier Olazarán et al. · Alzheimer s & Dementia Open access 27 Jul 2020 145
22 Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force Bruno J. Vellas et al. · Alzheimer s & Dementia 26 Jun 2013 145
23 36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease Hilkka S. Soininen, Alina Solomon, Pieter Jelle Visser et al. · Alzheimer s & Dementia Open access 13 Sep 2020 139
24 A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin et al. · Molecular Cancer Therapeutics 2 Sep 2015 135
25 The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort Pierre N. Tariot et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access 2018 131
26 An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease Jessica B. S. Langbaum, Suzanne B. Hendrix, Napatkamon Ayutyanont et al. · Alzheimer s & Dementia Open access 21 Apr 2014 128
27 The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease Cristina López López, Pierre N. Tariot, Angelika Caputo et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access 2019 119
28 Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis Gregor Ebert, Cody C. Allison, Simon Preston et al. · Proceedings of the National Academy of Sciences Open access 20 Apr 2015 118
29 Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2 Maurice Darding, Rebecca Feltham, Tencho Tenev et al. · Cell Death and Differentiation Open access 18 Feb 2011 106
30 The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach Richard Isaacson, Christine Anne Ganzer, Hollie Hristov et al. · Alzheimer s & Dementia Open access 13 Nov 2018 105
31 The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells Clemens Krepler, Srinivas K. Chunduru, Molly B. Halloran et al. · Clinical Cancer Research Open access 12 Feb 2013 104
32 Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics Najoua Lalaoui et al. · Cancer Cell Open access Feb 2016 102
33 Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus Gregor Ebert, Simon Preston, Cody C. Allison et al. · Proceedings of the National Academy of Sciences Open access 20 Apr 2015 96
34 Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease Roos J. Jutten, Kathryn V. Papp, Suzanne B. Hendrix et al. · Alzheimer s & Dementia Open access 10 Sep 2022 91
35 Challenges in developing Geroscience trials Yves Rolland et al. · Nature Communications Open access 19 Aug 2023 90
36 Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Craig M. McDonald et al. · The Lancet Open access Mar 2022 86
37 FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry” Marwan Noel Sabbagh, Suzanne B. Hendrix, John Harrison · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access 21 Dec 2018 84
38 Individualized clinical management of patients at risk for Alzheimer's dementia Richard Isaacson et al. · Alzheimer s & Dementia Open access 30 Oct 2019 79
39 Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis Alireza Atri, Suzanne B. Hendrix, Vojislav Pejović et al. · Alzheimer s Research & Therapy Open access 10 Mar 2015 75
40 Implementation of mechanism of action biology-driven early drug development for children with cancer Andrew D.J. Pearson et al. · European Journal of Cancer Open access Jun 2016 72
41 Prevention trials in Alzheimer's disease: An EU-US task force report Bruno J. Vellas, Paul S. S Aisen, Cristina Matos Sampaio et al. · Progress in Neurobiology 11 Sep 2011 68
42 Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial Sabrina Paganoni et al. · Journal of Neurology Neurosurgery & Psychiatry Open access 16 May 2022 67
43 Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study Hui Jing Yu, Samuel P. Dickson, Pei‐Ning Wang et al. · EBioMedicine Open access 29 Jun 2023 66
44 CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” Susan R. Abushakra, Anton P. Porsteinsson, B. Vellas et al. · The Journal of Prevention of Alzheimer s Disease Open access 2016 66
45 Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report Randall John Bateman, Kaj Blennow, Rachelle Smith Doody et al. · The Journal of Prevention of Alzheimer s Disease Open access Jul 2019 65
46 ‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings S P Dickson, Alette M. Wessels, S.A. Dowsett et al. · The Journal of Prevention of Alzheimer s Disease Open access 27 Apr 2023 60
47 Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo Leslie R. Coney, Bin Wang, Kenneth E. Ugen et al. · Vaccine Dec 1994 60
48 Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways Maria C. Tanzer, Nufail R. Khan, James A. Rickard et al. · Cell Death and Differentiation Open access 20 Jan 2017 59
49 Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL Goodwin G. Jinesh, Srinivas K. Chunduru, Ashish M. Kamat · Journal of Leukocyte Biology Open access 19 Apr 2012 59
50 Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligase Yoshio Nakatani, Torsten Kleffmann, Katrin Linke et al. · Biochemical Journal 3 Jan 2013 59

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.